Showing results (1701-1710 of 2,038) with videos related to

Sort By:
Pageof 204
JAMA Network Open|November 16, 2022
Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality TherapyAnthony M Magliocco, Jennifer Moughan, David T Miyamoto, et al.
Nature Medicine|March 31, 2015
Targeting the MLL complex in castration-resistant prostate cancerRohit Malik, Amjad P Khan, Irfan A Asangani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Nature Genetics|October 1, 2013
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complexJohn R Prensner, Matthew K Iyer, Anirban Sahu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancerJarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
Nature Cell Biology|September 7, 2021
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancerAlastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
European Urology|November 14, 2019
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized TrialsAmar U Kishan, Fang-I Chu, Christopher R King, et al.
Cancer Cell|May 18, 2011
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerJ Chad Brenner, Bushra Ateeq, Yong Li, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2017
Discovery of a 2'-fluoro-2'-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable propertiesThorsten A Kirschberg, Sammy Metobo, Michael O Clarke, et al.
Pageof 204